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MethodsBackground
The Hippo Pathway is a signaling pathway that regulates various 
essential biological processes including cellular proliferation, cell 
survival, differentiation, organ size, and tissue homeostasis. YAP1 
is a transcriptional co-activator and downstream effector in the 
Hippo pathway1. 
If overexpressed, YAP1 can become a highly potent oncogene 
that plays a major role tumorigenesis and metastasis in various 
types of cancer. This gene is overexpressed in 10% of all cancers 
and seen in many solid tumors either by genetic copy number 
amplification or by unknown pathways. 
YAP1 activation also leads to resistance to common cancer 
therapies such as cytotoxic chemotherapy, molecular targeted 
therapy and radiotherapy2.  Thus, targeting YAP1 requires 
nontraditional drug and cancer technology. 
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PROTACs are a novel drug technology that regulate protein 
function by completely degrading the target protein rather than 
inhibiting it. PROTACs are sensitive to drug resistant targets, 
effective at low concentrations, can target undruggable targets, 
and can influence nonenzymatic functions, making them unique 
from other drug technologies4.
Introduction
Since YAP1 plays an oncogenic role in many different cancers, it 
is important to target this protein for cancer treatment, however, 
it does not have any targetable enzymatic activity. This makes 
novel blocking strategies, such as PROTAC’s, important for 
possible treatment. Since YAP1 has been shown to be regulated 
by proteasomal mediated degradation, we reasoned that it may 
be possible to identify chemicals/PROTACS that promote YAP1 
degradation. To achieve this, we performed a high-throughput 
chemical screen to identify compounds/PROTACs that could 
degrade YAP1 proteins. Followed by western blot verification.
Conclusion
Our data show that these four novel molecules that can significantly reduce 
YAP1 protein levels in different cell lines. This data suggests that these 
compounds could be useful agents to target YAP1-dependent cancers and 
could offer significant improvements in a short amount of time. 
Future Direction
Our future steps include conducting proliferation assays using all the drugs 
on YAP1 independent and dependent cell lines. After this we hope to 
validate these results through in vivo studies. 
Results
Primary screening followed by secondary validation identified about 32 molecules with 
potential reduction of GFP levels tagged to the YAP1 protein. Some hits were further 
validated by YAP1 western blot which suggested that some of the identified 
compounds degraded YAP1. 
CIDD-015087, was identified as a lead compound in degrading YAP1. Through qSAR
of this compound three PROTACs, CIDD-0162266, CIDD-0162288, and CIDD-
0162289, were synthesized. The efficacy of these four compounds were measured in 
YAP1 independent and YAP1 dependent cell lines after 4 hours of treatment.
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Fig 1. Hippo Signaling Pathway Mechanism 
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Fig 2. PROTAC structure and mode of Action
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Fig 7. A: Proliferation assay results for CIDD-0150877. B: Proliferation results for 
PROTAC CIDD-0162266. C: Proliferation results for PRTOAC CIDD-0162288. D: 
Proliferation results for PROTAC CIDD-0162289. 
With all drugs at 20nM, we saw a reduction in YAP1 protein in both YAP1 
dependent and independent cell lines within 4 hours of treatment. 
The proliferation assay with the OV5 cell line showed a decrease in 
proliferation at high concentrations in the CIDD-0150877, CIDD-0162266, 
and CIDD-0162288 compounds. There was no decrease in proliferation at any 
concentration for compound CIDD-0162289. 
Fig 5 A-D. Western Blot and ImageJ analysis for YAP1 Dependent cell lines.
Below is a flow chart outlining the general procedures used in this study to 
discover and verify the PROTACs most effective in degrading YAP1 proteins. 
Fig 3. Study methodology








Fig 6 A-D. Western Blot and ImageJ analysis for YAP1 independent cell lines.
In compounds CIDD-0150877, CIDD-0162266, and CIDD-0162288, the two 
highest concentrations decreased the viability of the OV5 cells. OV5 cell line 
proliferation is not dependent on the presence of YAP1, these high 
concentrations may suggest toxicity to this cell line. The lack of any change at 
any concentration in the CIDD-0162289 assay suggest that the compound 
might not be effective.  
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